DK0682524T3 - Farmaceutiske præparater indeholdende et baktericid/permeabilitetsforøgende protein og et afspændingsmiddel - Google Patents

Farmaceutiske præparater indeholdende et baktericid/permeabilitetsforøgende protein og et afspændingsmiddel

Info

Publication number
DK0682524T3
DK0682524T3 DK94907963T DK94907963T DK0682524T3 DK 0682524 T3 DK0682524 T3 DK 0682524T3 DK 94907963 T DK94907963 T DK 94907963T DK 94907963 T DK94907963 T DK 94907963T DK 0682524 T3 DK0682524 T3 DK 0682524T3
Authority
DK
Denmark
Prior art keywords
bpi
pharmaceutical compositions
relaxant
bactericide
compositions containing
Prior art date
Application number
DK94907963T
Other languages
Danish (da)
English (en)
Inventor
Weldon Courtney Mcgregor
James Stubstad
Paul Chang
Original Assignee
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd filed Critical Xoma Technology Ltd
Application granted granted Critical
Publication of DK0682524T3 publication Critical patent/DK0682524T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK94907963T 1993-02-02 1994-02-02 Farmaceutiske præparater indeholdende et baktericid/permeabilitetsforøgende protein og et afspændingsmiddel DK0682524T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1236093A 1993-02-02 1993-02-02
PCT/US1994/001239 WO1994017819A1 (en) 1993-02-02 1994-02-02 Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant

Publications (1)

Publication Number Publication Date
DK0682524T3 true DK0682524T3 (da) 2002-01-28

Family

ID=21754603

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94907963T DK0682524T3 (da) 1993-02-02 1994-02-02 Farmaceutiske præparater indeholdende et baktericid/permeabilitetsforøgende protein og et afspændingsmiddel

Country Status (13)

Country Link
US (5) US5488034A (de)
EP (1) EP0682524B1 (de)
JP (2) JP3946246B2 (de)
CN (1) CN1163264C (de)
AT (1) ATE206308T1 (de)
AU (1) AU695125B2 (de)
CA (1) CA2155005C (de)
DE (1) DE69428521T2 (de)
DK (1) DK0682524T3 (de)
ES (1) ES2164098T3 (de)
HK (1) HK1014156A1 (de)
PT (1) PT682524E (de)
WO (1) WO1994017819A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277410B1 (en) 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5488034A (en) 1993-02-02 1996-01-30 Xoma Corporation Pharmaceutical composition comprising BPI proteins
US6214789B1 (en) 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5731415A (en) 1993-06-17 1998-03-24 Xoma Corporation Lipopolysaccharide binding protein derivatives
WO1995002414A1 (en) * 1993-07-14 1995-01-26 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
US6759203B1 (en) 1993-09-22 2004-07-06 Xoma Corporation Method for quantifying BPI in body fluids
DE69430823T2 (de) * 1993-09-22 2003-02-20 Xoma Technology Ltd Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
WO1995019180A1 (en) * 1994-01-14 1995-07-20 Xoma Corporation Anti-gram-positive bacterial methods and materials
DE69526216T2 (de) * 1994-01-14 2002-11-14 Xoma Technology Ltd Antifungaleverfahren und mitteln
US5447913A (en) 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5830860A (en) * 1994-03-24 1998-11-03 Regents Of The University Of Minnesota Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5932544A (en) 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
US6271203B1 (en) 1994-07-07 2001-08-07 Xoma Corporation Anti-protozoan methods and materials
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
CA2227292A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
AU730307B2 (en) * 1995-11-14 2001-03-01 Xoma Corporation Bactericidal permeability increasing protein (BPI) for treating conditions associated with corneal injury
US5741779A (en) 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
WO1997042966A1 (en) * 1996-05-10 1997-11-20 Xoma Corporation Therapeutic uses of bpi protein products for human meningococcemia
NZ332954A (en) * 1996-05-23 2000-07-28 Xoma Corp Use of BPI protein products to treat humans with hemorrhage due to trauma
EP0939766A2 (de) 1996-05-24 1999-09-08 The Regents Of The University Of Minnesota Synthese von löslichen beta-sheet bildenden peptiden
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
AU6358898A (en) * 1996-09-09 1998-04-17 Alexander V Kabanov Fluorinated copolymeric pharmaceutical adjuncts
AU744918B2 (en) * 1996-11-01 2002-03-07 Xoma Corporation Therapeutic uses of BPI protein products in cystic fibrosis patients
US6482796B2 (en) * 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
FR2764800B1 (fr) * 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US5990082A (en) 1997-10-22 1999-11-23 Xoma Corporation Uses of lipopolysaccharide binding protein
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
WO2000062795A2 (en) * 1999-04-21 2000-10-26 The Government Of The United States Of America, Represented By The Secretary, Department Of Healt H And Human Services The National Institutes Of Health UTEROGLOBIN IN THE TREATMENT OF IgA MEDIATED AUTOIMMUNE DISORDERS
US6413537B1 (en) 2000-03-10 2002-07-02 Wisconsin Alumni Research Foundation Nystatin formulation having reduced toxicity
US7256180B2 (en) 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
AU2002335815A1 (en) * 2001-10-16 2003-04-28 Rxkinetix, Inc. High-concentration protein formulations and method of manufacture
EP1572719A4 (de) 2002-02-20 2007-11-14 Univ Minnesota Partielle peptidmimetika und verfahren
WO2004007520A2 (en) * 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
EP1567191B1 (de) * 2002-11-26 2010-09-08 Eurocine Vaccines AB Neue adjuvant auf der basis von aminen
KR101235507B1 (ko) * 2003-02-28 2013-02-20 추가이 세이야쿠 가부시키가이샤 단백질을 함유하는 안정화 제제
KR101105486B1 (ko) * 2003-04-02 2012-01-13 아레스 트레이딩 에스.에이. Ｆｓｈ 및 ｌｈ과 비이온성 계면활성제의 액상 약제학적 제제
US7838721B2 (en) * 2003-04-09 2010-11-23 Paragon Trade Brands, Llc Disposable articles using high column AUL superabsorbents
CA2526099C (en) * 2003-06-20 2013-02-05 Ares Trading Sa Freeze-dried fsh / lh formulations
US8377459B2 (en) * 2003-07-09 2013-02-19 The Procter & Gamble Company Composition for wet wipes that enhances the efficacy of cleansing while being gentle to the skin
US20050220881A1 (en) * 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition
US7150995B2 (en) * 2004-01-16 2006-12-19 Metrika, Inc. Methods and systems for point of care bodily fluid analysis
EP1776137B1 (de) * 2004-08-04 2014-11-26 Ipsen Biopharm Limited Pharmazeutische zusammensetzung enthaltend botulinum neurotoxin a2
EP1778279B1 (de) * 2004-08-04 2014-12-03 Ipsen Biopharm Limited Pharmazeutische zusammensetzung mit botulinum neurotoxin a2
US20060173428A1 (en) * 2005-02-02 2006-08-03 Acors Deanna M Absorbent article with logically correlated image and textual graphics
EP1885393A4 (de) 2005-05-18 2011-03-02 Childrens Hosp & Res Ct Oak Verfahren und zusammensetzungen zur immunisierung gegen chlamydien-infektionen
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
WO2009021173A1 (en) * 2007-08-08 2009-02-12 Advanced Liquid Logic, Inc. Use of additives for enhancing droplet operations
JP5387850B2 (ja) * 2007-09-12 2014-01-15 Ｊｓｒ株式会社 タンパク安定化剤およびその製造方法、タンパク安定化剤の使用方法、ならびにタンパク安定化方法
PT2310412T (pt) 2008-06-20 2018-05-28 Novartis Ag Imunoglobulinas com agregação reduzida
MX338775B (es) 2009-06-04 2016-05-02 Novartis Ag Metodos para identificacion de sitios para conjugacion de igg.
PT2585104T (pt) * 2010-06-25 2019-10-30 Shire Human Genetic Therapies Métodos e composições de arilsulfatase a para a administração no snc
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US9090691B2 (en) 2010-09-15 2015-07-28 Applied Molecular Transport Llc Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
GB201116271D0 (en) 2011-09-21 2011-11-02 Univ Cardiff Dispersion anaesthetic device
CN106470707A (zh) 2014-05-07 2017-03-01 应用分子运输有限责任公司 用于口服递送生物活性货物的cholix毒素衍生的融合分子
WO2019173787A1 (en) 2018-03-08 2019-09-12 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
EP3762009B1 (de) 2018-03-08 2022-05-11 Applied Molecular Transport Inc. Von toxinen abgeleitete konstrukte zur oralen verabreichung
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
JP2023517511A (ja) * 2020-03-18 2023-04-26 ジーアイ イノベーション， インコーポレイテッド Ｉｌ－２タンパク質とｃｄ８０タンパク質を含む融合タンパク質製剤
JP2022151814A (ja) * 2021-03-24 2022-10-07 Ｊｃｒファーマ株式会社 安定な水性医薬組成物又は凍結乾燥医薬組成物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839314A (en) * 1971-06-29 1974-10-01 Baxter Laboratories Inc Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene
US4478829A (en) * 1983-04-28 1984-10-23 Armour Pharmaceutical Company Pharmaceutical preparation containing purified fibronectin
US4933179A (en) * 1983-08-22 1990-06-12 Syntex (U.S.A.) Inc. Feline leukemia virus antigen vaccines
DE3406497A1 (de) * 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung
US5234683A (en) * 1985-06-18 1993-08-10 Emory University Method of stimulating the immune system
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5039520A (en) * 1986-05-15 1991-08-13 Emory University Plasma extender
US5182106A (en) * 1986-05-15 1993-01-26 Emory University Method for treating hypothermia
US5071649A (en) * 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
US5152979A (en) * 1986-05-15 1992-10-06 Emory University Method for treating vascular obstructions caused by abnormal cells
US5041288A (en) * 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
EP0305470B1 (de) * 1987-02-20 1992-11-11 Emory University Antiinfektiöse verbindungen und verfahren zur verwendung
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
DE3853918T2 (de) * 1987-08-11 1996-02-08 Univ New York Biologisch aktive bakterientötende/durchlässigkeitserhöhende proteinfragmente.
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH02107163A (ja) * 1988-10-15 1990-04-19 Suntory Ltd 新規なゲル状食品の製造方法
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US4997664A (en) * 1989-09-05 1991-03-05 Bryan Foods, Inc. Method for packaging food products
DE69128968T2 (de) * 1990-12-03 1998-10-08 Univ New York Biologisch aktive bakterizide/permeabilitätserhöhende proteinbruchstücke
IE920860A1 (en) * 1991-03-19 1992-09-23 Cytrx Corp Polyoxypropylene/polyoxyethylene copolymers with improved¹biological activity
US5234908A (en) * 1991-04-12 1993-08-10 Creative Biomolecules, Inc. Method of treating gastrointestinal ulcers with platelet derived growth factor
AU2872792A (en) * 1991-09-26 1993-04-27 Incyte Pharmaceuticals, Inc. A new form of liposaccharide binding protein (lbp)
ES2132239T3 (es) * 1992-05-19 1999-08-16 Xoma Corp Metodos mejorados para la preparacion de proteinas de union a endotoxinas.
WO1993023434A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
US5488034A (en) * 1993-02-02 1996-01-30 Xoma Corporation Pharmaceutical composition comprising BPI proteins
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products

Also Published As

Publication number Publication date
EP0682524B1 (de) 2001-10-04
US6066620A (en) 2000-05-23
JP3946246B2 (ja) 2007-07-18
EP0682524A1 (de) 1995-11-22
CA2155005A1 (en) 1994-08-18
CA2155005C (en) 1999-04-06
JPH10513433A (ja) 1998-12-22
ES2164098T3 (es) 2002-02-16
HK1014156A1 (en) 1999-09-24
US5955427A (en) 1999-09-21
US5488034A (en) 1996-01-30
PT682524E (pt) 2002-03-28
CN1163264C (zh) 2004-08-25
US5696090A (en) 1997-12-09
CN1127992A (zh) 1996-07-31
AU6133094A (en) 1994-08-29
DE69428521D1 (de) 2001-11-08
DE69428521T2 (de) 2002-05-23
AU695125B2 (en) 1998-08-06
JP2005145986A (ja) 2005-06-09
ATE206308T1 (de) 2001-10-15
US6255284B1 (en) 2001-07-03
WO1994017819A1 (en) 1994-08-18

Similar Documents

Publication Publication Date Title
DK0682524T3 (da) Farmaceutiske præparater indeholdende et baktericid/permeabilitetsforøgende protein og et afspændingsmiddel
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
NL300212I1 (nl) ASP-B28 insulinekristallen.
FI962154A (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
DK0679092T3 (da) Cytokindæmpende midler
ATE177757T1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
CA2138161A1 (en) Glucagon-like peptide and insulinotropin derivatives
DK0749317T3 (da) Terapeutiske anvendelser af dimerprodukter af baktericidt/permeabilitetsforøgende protein
IT1212778B (it) Composizioni farmaceutiche adattivita' antiinfiammatoria e/o analgesica, non ulcerogene.
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
BR0211186A (pt) peptìdeos e uso dos mesmos no escurecimento da pele
AU3078892A (en) Human interleukin-8 analogs
ATE103776T1 (de) Neue n-(sulfomethyl)-n'-arylharnstoffe.
ES2087337T3 (es) Composiciones de implantes que contienen una proteina, peptido o polipeptido biologicamente activos.
DE69312319D1 (de) Tachyquinin antagonisten, ihre herstellung und ihre verwendung in pharmazeutischen formulierungen
HRP20000781B1 (en) Effervescent preparations
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
ATE208627T1 (de) Orale zusammensetzungen mit niedrigdosierten zytotoxischen proteinen
HUP0000812A2 (hu) Myelin bázikus fehérje peptid-fragmentumai az azokat tartalmazó gyógyszerkészítmények és felhasználásuk a sclerosis multiplex kezelésére
CA2247998A1 (en) Fragments of cr1 and their use
ATE239499T1 (de) Protein-disulfid-isomerasen enthaltende pharmazeutische zusammensetzungen
CA2153071A1 (en) Derivatized calcitonins
ITMI922332A1 (it) Composizioni farmaceutiche per la somministrazione di paratormone, suoi frammenti biologicamente attivi o peptidi correlati per via rettale.
ITMI932544A0 (it) Composizioni farmaceutiche e/o dermocosmetologiche e cosmetiche contenenti colostro bovino.